Thomas Woiwode Insider Trading $CRSP CRISPR Therapeutics AG
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Thomas Woiwode.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Thomas Woiwode. Thomas Woiwode is Director in Adverum Biotechnologies, Inc. ($AAVL) and Director in Audentes Therapeutics, Inc. ($BOLD) and Director in CRISPR Therapeutics AG ($CRSP) and Director in Gritstone Oncology, Inc. ($GRTS) and Director in Passage BIO, Inc. ($PASG) and Director in Aligos Therapeutics, Inc. ($ALGS).
Thomas Woiwode in CRISPR Therapeutics AG
Trading Symbol: CRSPIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Thomas Woiwode: Director
Holdings: 641,014 shares
Current Value: $10,095,971
Latest Transaction: Jun 15 2018
$CRSP Market Capitalization: $605.88M
$CRSP Previous Close: $15.75
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Thomas Woiwode in CRISPR Therapeutics AG
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADVM, ALGS, BOLD, CRSP, GRTS, PASG
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | A | 59.31 | 30,000 | 1,779,300 | 30,000 | |
Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | A | 59.31 | 30,000 | 1,779,300 | 30,000 | |
May 17 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 58.73 | 1,000 | 58,730 | 640,014 | 641 K to 640 K (-0.16 %) |
May 17 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 57.97 | 43,000 | 2,492,710 | 641,014 | 684 K to 641 K (-6.29 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.45 | 1,653 | 85,047 | 5,629 | 7.3 K to 5.6 K (-22.70 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.26 | 582 | 29,833 | 90,730 | 91.3 K to 90.7 K (-0.64 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.26 | 249 | 12,764 | 38,772 | 39 K to 38.8 K (-0.64 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.26 | 225 | 11,534 | 34,977 | 35.2 K to 35 K (-0.64 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.26 | 7,645 | 391,883 | 1,192,139 | 1.2 M to 1.2 M (-0.64 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.31 | 7,424 | 373,501 | 91,312 | 98.7 K to 91.3 K (-7.52 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.31 | 3,172 | 159,583 | 39,021 | 42.2 K to 39 K (-7.52 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.31 | 2,862 | 143,987 | 35,202 | 38.1 K to 35.2 K (-7.52 %) |
May 09 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.31 | 97,550 | 4,907,741 | 1,199,784 | 1.3 M to 1.2 M (-7.52 %) |
May 02 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.29 | 2,044 | 102,793 | 98,736 | 100.8 K to 98.7 K (-2.03 %) |
May 02 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.26 | 874 | 43,927 | 42,193 | 43.1 K to 42.2 K (-2.03 %) |
May 02 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.29 | 788 | 39,629 | 38,064 | 38.9 K to 38.1 K (-2.03 %) |
May 02 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.29 | 26,860 | 1,350,789 | 1,297,334 | 1.3 M to 1.3 M (-2.03 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.03 | 779 | 38,973 | 100,780 | 101.6 K to 100.8 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.03 | 779 | 38,973 | 100,780 | 101.6 K to 100.8 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.01 | 333 | 16,653 | 43,067 | 43.4 K to 43.1 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.01 | 333 | 16,653 | 43,067 | 43.4 K to 43.1 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.08 | 300 | 15,024 | 38,852 | 39.2 K to 38.9 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.08 | 300 | 15,024 | 38,852 | 39.2 K to 38.9 K (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.02 | 10,236 | 512,005 | 1,324,194 | 1.3 M to 1.3 M (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.02 | 10,236 | 512,005 | 1,324,194 | 1.3 M to 1.3 M (-0.77 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.11 | 14,086 | 705,849 | 101,559 | 115.6 K to 101.6 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.11 | 14,086 | 705,849 | 101,559 | 115.6 K to 101.6 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.12 | 6,019 | 301,672 | 43,400 | 49.4 K to 43.4 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.12 | 6,019 | 301,672 | 43,400 | 49.4 K to 43.4 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.12 | 5,430 | 272,152 | 39,152 | 44.6 K to 39.2 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.12 | 5,430 | 272,152 | 39,152 | 44.6 K to 39.2 K (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.11 | 185,075 | 9,274,108 | 1,334,430 | 1.5 M to 1.3 M (-12.18 %) |
Apr 30 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.11 | 185,075 | 9,274,108 | 1,334,430 | 1.5 M to 1.3 M (-12.18 %) |
Apr 26 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.00 | 1,528 | 77,928 | 115,645 | 117.2 K to 115.6 K (-1.30 %) |
Apr 26 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.00 | 653 | 33,303 | 49,419 | 50.1 K to 49.4 K (-1.30 %) |
Apr 26 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.60 | 589 | 29,803 | 44,582 | 45.2 K to 44.6 K (-1.30 %) |
Apr 26 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.00 | 20,071 | 1,023,621 | 1,519,505 | 1.5 M to 1.5 M (-1.30 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.66 | 6,821 | 345,552 | 117,173 | 124 K to 117.2 K (-5.50 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.00 | 2,915 | 148,665 | 50,072 | 53 K to 50.1 K (-5.50 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 51.00 | 2,630 | 134,130 | 45,171 | 47.8 K to 45.2 K (-5.50 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 50.66 | 89,628 | 4,540,554 | 1,539,576 | 1.6 M to 1.5 M (-5.50 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 2,323 | 0 | 7,282 | 5 K to 7.3 K (+46.84 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 92,918 | 0 | 0 | 92.9 K to 0 (-100.00 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 92,918 | 0 | 92,918 | 0 to 92.9 K |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 2,947 | 0 | 13,277 | 16.2 K to 13.3 K (-18.16 %) |
Apr 24 2018 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 497,053 | 0 | 2,238,979 | 2.7 M to 2.2 M (-18.17 %) |
Dec 27 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 20.29 | 3,059 | 62,070 | 4,959 | 8 K to 5 K (-38.15 %) |
Nov 28 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 20.24 | 200 | 4,048 | 8,018 | 8.2 K to 8 K (-2.43 %) |
Nov 28 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | S | 20.21 | 1,700 | 34,358 | 8,218 | 9.9 K to 8.2 K (-17.14 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 9,918 | 0 | 9,918 | 0 to 9.9 K |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 1,240 | 0 | 0 | 1.2 K to 0 (-100.00 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 1,240 | 0 | 1,240 | 0 to 1.2 K |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 17,283 | 0 | 0 | 17.3 K to 0 (-100.00 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 17,283 | 0 | 17,283 | 0 to 17.3 K |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 292,529 | 0 | 0 | 292.5 K to 0 (-100.00 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | J | 0.00 | 292,529 | 0 | 292,529 | 0 to 292.5 K |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 26,491 | 0 | 52,987 | 79.5 K to 53 K (-33.33 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 61,993 | 0 | 123,994 | 186 K to 124 K (-33.33 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 23,899 | 0 | 47,801 | 71.7 K to 47.8 K (-33.33 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 814,599 | 0 | 1,629,204 | 2.4 M to 1.6 M (-33.33 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 8,110 | 0 | 16,224 | 24.3 K to 16.2 K (-33.33 %) |
Sep 07 2017 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Sell | J | 0.00 | 1,368,013 | 0 | 2,736,032 | 4.1 M to 2.7 M (-33.33 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 5,774 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 13,180 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 5,210 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 173,167 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 1,454 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 231,077 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 73,704 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 168,224 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 66,490 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 2,210,417 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 19,524 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 3,100,477 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 2,754 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | C | 0.00 | 437,247 | 0 | 0 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | A | 14.00 | 30,000 | 420,000 | 60,000 | |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 5,774 | 0 | 79,478 | 73.7 K to 79.5 K (+7.83 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 73,704 | 0 | 73,704 | 0 to 73.7 K |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | P | 14.00 | 4,583 | 64,162 | 185,987 | 181.4 K to 186 K (+2.53 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 13,180 | 0 | 181,404 | 168.2 K to 181.4 K (+7.83 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 168,224 | 0 | 168,224 | 0 to 168.2 K |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 5,210 | 0 | 71,700 | 66.5 K to 71.7 K (+7.84 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 66,490 | 0 | 66,490 | 0 to 66.5 K |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | P | 14.00 | 60,219 | 843,066 | 2,443,803 | 2.4 M to 2.4 M (+2.53 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 173,167 | 0 | 2,383,584 | 2.2 M to 2.4 M (+7.83 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 2,210,417 | 0 | 2,210,417 | 0 to 2.2 M |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | P | 14.00 | 602 | 8,428 | 24,334 | 23.7 K to 24.3 K (+2.54 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 1,454 | 0 | 23,732 | 22.3 K to 23.7 K (+6.53 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 19,524 | 0 | 22,278 | 2.8 K to 22.3 K (+708.93 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 2,754 | 0 | 2,754 | 0 to 2.8 K |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | P | 14.00 | 95,596 | 1,338,344 | 4,104,045 | 4 M to 4.1 M (+2.38 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 231,077 | 0 | 4,008,449 | 3.8 M to 4 M (+6.12 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 3,100,477 | 0 | 3,777,372 | 676.9 K to 3.8 M (+458.04 %) |
Dec 23 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Buy | C | 0.00 | 437,247 | 0 | 676,895 | 239.6 K to 676.9 K (+182.45 %) |
Oct 20 2016 | CRSP | CRISPR Therapeutic ... | Woiwode Thomas | Director | Option Exercise | A | 14.00 | 30,000 | 420,000 | 30,000 |
Page: 1